MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]

In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.

I hope you stay till the end and are able to get some value from this discussion.

TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .

TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.

Timestamps:
0:00 – Intro
0:40 – TRYP’s mission and Greg Mckee’s personal involvement
2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
14:29 – Clinical trial progress and anticipated start of Phase IIa trials
18:26 – Anticipated commercialization timelines
21:34 – TRYP Therapeutics’ competitive advantage
27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Pertinent links:
Tryp Therapeutics’ Mission:
https://tryptherapeutics.com/

Tryp’s pipeline progress:
https://tryptherapeutics.com/pipeline/

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .

https://tryptherapeutics.com/
CSE: TRYP | OTC: TRYPF

#TRYP #TrypTherapeutics #TrypStock

The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor

Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.

Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).

Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks

#Psychedelics #MindMed #Investing

A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic.
This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%.
For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b.
Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
James Twitter: @PSY_Invest
Maria’s Twitter: @PSY_Holy

Facebook: @thepsychedelicinvestor

Email: thepsychedelicinvestor@gmail.com

Music: www.bensound.com

Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #Psilocybin #Psychedelics

Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.

The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).

Hope you guys enjoy this video!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #mmed #mindmedstock
Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU